DSIP (delta sleep-inducing peptide) is a peptide first identified in rabbit research studied for its proposed role in sleep regulation and stress response. Human data is limited and its mechanism is not fully established.
DSIP (Delta Sleep-Inducing Peptide) is a naturally-occurring nonapeptide first isolated from rabbit brain. It has a genuinely old and real — if mixed — human trial history, unlike most compounds in this category.
Acute effect (human, n=6, double-blind crossover): sleep increased 59% within 130 minutes of treatment vs. placebo, with no psychological, physiological, or biochemical side effects observed. Schneider-Helmert et al., Int J Clin Pharmacol Ther Toxicol, 1981
Chronic insomnia (human, n=16, double-blind): a more rigorous trial in actual chronic insomniacs found objective measures (sleep efficiency, latency) improved modestly, but subjective sleep quality showed no meaningful change — the authors concluded short-term DSIP treatment "is not likely to be of major therapeutic benefit" for this population. Bes et al., Neuropsychobiology, 1992
The honest synthesis: DSIP produces a real, measurable acute sleep effect in healthy volunteers, but the one trial in the population it would actually be used for (chronic insomnia) found the benefit was weak, not the dramatic effect the acute study might suggest.
No dose was independently re-verified with full detail in this pass across either trial — DSIP's trial history is real but decades old (1980s-90s), predating modern reporting standards. Community-use conventions weren't checked against a primary source.
The acute healthy-volunteer study reported no side effects of any kind. No adverse-event-specific data was found from the chronic-insomnia trial beyond the efficacy finding above.
Sleep regulation, particularly slow-wave sleep, and stress-response signaling.
No, it is not an approved drug and is sold for research use only.
The name reflects the context in which it was originally identified; its exact mechanism of action is still not fully established in the literature.
Modest, but real. Human studies show improved sleep efficiency and shorter time to fall asleep versus placebo, and animal studies show a genuine increase in the deep, slow-wave brain activity tied to restorative sleep. Not a knockout sedative — a real but measured effect.
Mostly because the effect size is smaller than GH-axis peptides and the mechanism is so poorly understood — pharma companies gravitate toward compounds with a clear, provable mechanism they can build an approval case around, and DSIP never gave them that.
Looking for something specific, or placing a wholesale order? Send us a DM or email.